LYEL
Lyell Immunopharma, Inc.Price
Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).
- Feb 10 to Feb 11 ▼ 2 days of insider sells: $264.3K by 4 insiders, avg $23.37
- Mar 6 ▲ Two funds affiliated with ARCH Venture Partners collectively purchas…
- Jun 10 ▼ 1 insider sell $25.0K at $12.64
- Jul 16 to Jul 17 ▼ 2 days of insider sells: $274.30 by 1 insider, avg $13.72
- Aug 6 Stifel initiates
- Aug 10 ▼ 4 insiders sell $17.7K at $14.34
- Aug 21 ▼ 3 insiders sell $187.0K at $15.54
- Sep 10 ▼ 1 insider sell $6.3K at $12.70
- Oct 12 ▼ 1 insider sell $3.6K at $8.63
- Nov 4 ▲ 2 insiders buy $50.0M at $10.77
- Nov 4 Contract: Lyell Immunopharma Announces $80 Million Private Placement…
- Nov 10 ▼ 4 insiders sell $18.8K at $15.93
Signal stack
Where each data set points today.
- InsidersBULLISH
2 insiders bought $75.0M at an average $13.35. 7 insiders sold $538.6K. Price is 10% above their cost.
- InstitutionsBULLISH
Q3 2026: 20 added (0 new), 5 trimmed or exited.
- AnalystsBULLISH
12 of 14 rate it Buy or better.
- EstimatesRISING
Current-quarter EPS estimate −$1.610 → −$1.570 over 90 days. 1 up, 0 down in 30 days.
- Short sellersSTEADY
Short interest +0.8% to 1.41M shares. 10.4 days to cover, ≈5.7% of shares.
- TrendUPTREND
33% above its 50-day average.
Who's buying
13F· Q3 2026| Fund | Move | Value |
|---|---|---|
| RENAISSANCE TECHNOLOGIES LLC | ADD | $1.9M |
| Qube Research & Technologies Ltd | ADD | $1.4M |
| MORGAN STANLEY | DOUBLED | $875.5K |
| UBS Group AG | DOUBLED | $823.7K |
| JPMORGAN CHASE & CO | DOUBLED | $477.7K |
| DIMENSIONAL FUND ADVISORS LP | TRIM | $454.2K |
| RHUMBLINE ADVISERS | ADD | $252.4K |
| BNP PARIBAS FINANCIAL MARKETS | DOUBLED | $248.8K |
Quarterly 13F filings are due 45 days after each quarter ends.
The Street
14 analysts| Date | Firm | Rating |
|---|---|---|
| Nov 13, 2026 | HC Wainwright & Co. MAINTAIN | Buy |
| Nov 3, 2026 | Needham REITERATE | Buy |
| Sep 11, 2026 | Needham REITERATE | Buy |
| Aug 6, 2026 | Stifel INITIATE | Buy |
| Jul 22, 2026 | B. Riley Securities INITIATE | Buy |
| Jun 15, 2026 | Citizens REITERATE | Market Outperform |
Insider ledger
Form 4| Insider | Type | Value |
|---|---|---|
Bulis Veronica Sanchez VP, Corporate Controller Nov 10, 2026 | SELL | $6.6K |
Seely Lynn President and CEO Nov 10, 2026 | SELL | $8.7K |
Hill Stephen J. Chief Operating Officer Nov 10, 2026 | SELL | $1.4K |
Lee Gary K. Chief Scientific Officer Nov 10, 2026 | SELL | $2.1K |
ARCH Venture Fund XIII, L.P. 10%+ Owner Nov 4, 2026 | BUY | $25.0M |
ARCH Venture Partners IX, LLC 10%+ Owner Nov 4, 2026 | BUY | $25.0M |
Aguirre Jarrad Mattieu Chief Medical Officer Oct 12, 2026 | SELL | $3.6K |
Aguirre Jarrad Mattieu Chief Medical Officer Sep 10, 2026 | AWARD | 47,500 sh |
Earnings setup
Estimates| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | -$1.57 | -$1.57–-$1.57 | +2.5% | $6.7K |
| Next Q | -$1.69 | -$1.79–-$1.61 | +20.3% | $5.0K |
| Current FY | 🔒 Fresh data, subscribers only | |||
| Next FY | 🔒 Fresh data, subscribers only | |||
Short side
FINRA· Oct 30, 2026SecBot reports
15 filings · 6 press releases · 3 bullish · 1 bearish · 1 mixed · 10 neutral- NEUTRAL S-3Nov 13, 2026
Lyell Immunopharma filed an S-3 registration statement to register 7,428,040 shares of common…
The resale registration is a routine contractual step following the private placement. Monitor the pace of selling by the institutional holders listed in the filing, as their sales could create…
- BULLISH CLUSTERNov 12, 2026
Two 10% owner affiliates of ARCH Venture Partners purchased $50M in open-market shares on November…
The $50M insider purchase by ARCH Venture Partners affiliates is a strong vote of confidence in Lyell's prospects, particularly given the timing with the Q3 earnings release and positive ronde-cel…
- NEUTRAL SC 13G/ANov 10, 2026
ARCH Venture Fund IX, L.P. and affiliated entities filed an amended Schedule 13G disclosing a…
ARCH's passive stake is unchanged, indicating no shift in investor sentiment. Monitor for any future conversion to a 13D filing, which would signal activist intent, but no such signal is present here.
- BULLISH CLUSTERNov 5, 2026
Two ARCH Venture affiliates (10% owners) purchased a combined 4.64M shares of Lyell Immunopharma…
The $50M insider purchase by two ARCH affiliates at $10.77 per share, representing ~19% of market cap, is an extraordinary vote of confidence. Monitor for potential additional insider buying or a…
All LYEL filing & press-release reports (21)
- S-3 reportNov 13, 2026
- CLUSTER reportNov 12, 2026
- SC 13G/A reportNov 10, 2026
- CLUSTER reportNov 5, 2026
- 8-K reportNov 4, 2026
- PRESS-RELEASE reportNov 4, 2026
- 8-K reportNov 4, 2026
- PRESS-RELEASE reportNov 4, 2026
- CLUSTER reportAug 25, 2026
- EFFECT reportJul 22, 2026
- CLUSTER reportJun 15, 2026
- PRESS-RELEASE reportJun 12, 2026
- PRESS-RELEASE reportJun 8, 2026
- PRESS-RELEASE reportJun 4, 2026
- DEFA14A reportApr 24, 2026
- EFFECT reportApr 15, 2026
- S-3 reportApr 3, 2026
- PRESS-RELEASE reportMar 12, 2026
- CLUSTER reportMar 6, 2026
- PRESS-RELEASE reportMar 9, 2026
- INST-CLUSTER reportFeb 28, 2026